Aurora Cannabis appears caught in a structural revenue contraction, with sales falling 23.4% year-over-year to $67.6M in 2027Q1 following a 57.9% decline in 2026Q4, while SG&A held steady near $40.9M per quarter, converting modest demand weakness into a $47.5M operating loss and a -70.2% operating margin.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $0.03+200.0% vs -$0.03 | $61M+19.5% vs $51M |
Q3 2026 Aug 5, 2026 | -$0.05+64.6% vs -$0.13 | $48M+0.2% vs $47M |
Q3 2026 Jun 11, 2026 | -$0.71-914.1% vs -$0.07 | $61M+12.0% vs $54M |
Q1 2026 Feb 4, 2026 | $0.02-75.9% vs $0.10 | $69M+2.0% vs $67M |
Aurora Cannabis Inc. (ACB) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to earnings of $0.09 per share a year ago.
EDMONTON, Alberta--(BUSINESS WIRE)--Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ | TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter 2027 ending September 30, 2026. Aurora has cancelled its investor call, originally scheduled for November 12, 2026, at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time, due to the Company's announcement on November 3, 2026, that Aurora has entered into a defin.
Aurora Cannabis shares surged after Organigram agreed to a C$561 million buyout, but competing bids, deal conditions and shareholder uncertainty remain.
STAMFORD, Conn., Nov. 3, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf"), a leading international provider of consumer and medical cannabis products, today acknowledges the announcement by Aurora Cannabis Inc. (TSX: ACB) (NASDAQ: ACB) ("Aurora") of an alternative transaction from Organigram Global Inc. ("Organigram").
Benchmark ACB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Aurora Cannabis Inc. (ACB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.24 | $324.58M | -4.12 | -6.61% | -38.15% | -20.36% | — | |
| $0.65 | $275.66M | -1.24 | 5.8% | -88.67% | -37.43% | — | |
| $2.92 | $389.35M | -2.37 | 11.46% | -17.05% | -9.54% | — | |
| $3.61 | $1.35B | 21.60 | 26.81% | 22.84% | 5.11% | — | |
| $0.88 | $123.4M | 1.95 | 16.42% | 28.02% | 21.02% | — | |
| $64.71 | $3.76B | 36.12 | -3.64% | 3.16% | — | 4.05% |
Aurora Cannabis Inc. (ACB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ACB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Aurora Cannabis Inc. (ACB) stock FAQ — growth, dividends, profitability & financials explained
Aurora Cannabis Inc. (ACB) reported $290.3M in revenue over the trailing twelve months. Revenue was $320.6M in fiscal year 2026.
Aurora Cannabis Inc. (ACB) revenue fell by 16.6% over the trailing twelve months, compared with the twelve months before.
No. Aurora Cannabis Inc. (ACB) reported a net loss of $110.7M over the trailing twelve months.
Aurora Cannabis Inc. (ACB) had a return on equity (ROE) of -20.4% over the trailing twelve months. A negative ROE means the company lost money over the period.
Aurora Cannabis Inc. (ACB) had negative free cash flow of $51.0M over the trailing twelve months.
